NCT07899697Active, not recruiting

Feasibility Study of Middle Segmental Gastrectomy (MSG) for Gastric Cancer.

A Multicenter, Prospective, Single-arm Clinical Trial on the Feasibility of Middle Segmental Gastrectomy (MSG)

Source: ClinicalTrials.gov · Last updated 27 Oct 2026

Brief summary (registry, in English)

This multicenter, prospective, single-arm phase 2 clinical trial aims to evaluate the safety, feasibility, and clinical applicability of Middle Segmental Gastrectomy (MSG) for patients with gastric cancer * MSG is a function-preserving surgical technique that resects the middle portion of the stomach while preserving the pylorus and the upper stomach (cardia and fundus) to minimize common postoperative issues such as dumping syndrome and nutritional deficiencies The primary objective of the study is to determine the incidence of dumping syndrome at 1 year postoperatively (defined as a Sigstad score ≥ 7) and evaluate if it differs significantly from the 15.8% incidence reported for standard laparoscopic distal gastrectomy (LDG) in the KLASS 04 study . The study targets adult patients with mid- or high-body gastric adenocarcinoma with a tumor size of 4 cm or less at clinical stages cT1N0/1M0 or cT2N0/1M0 (well or moderately differentiated) . Secondary evaluations include monitoring postoperative reflux symptoms, changes in nutritional indicators (such as weight and hemoglobin), quality of life (QOL) using EORTC QLQ-C30 and STO22, and 3-year recurrence-free and overall survival rates.

Status (registry): Active, not recruiting
Study type: Interventional
Enrollment: 78 (estimated)
First submitted: 7 Oct 2026
Start date: 15 Jun 2025
Primary completion date: 14 Jun 2028
Lead sponsor: National Cancer Center, Korea
Diseases: Gastric and esophageal cancer
NCT number: NCT07899697

What you commit to

Study type: Interventional
Planned participants: 78
From 15 Jun 2025 to the primary completion date, 14 Jun 2028
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

Borrmann type 4 stomach cancer
- Multiple gastric cancers or comorbid malignancies
- Boundaries of the lesion are unclear
- Clear mesenteric infiltration (T4) was determined at surgery. ⑤ Two or more lymph node infiltrates are visually connected at the time of surgery.
- ⑥ Patients with other malignancies that affect gastric function preservation metrics
- \- A history of cancer in other organs
- Cancer in other organs
- Patients with A history of gastrectomy surgery ⑦ Vulnerable populations (incapacitated, pregnant, or planning to become pregnant) ⑧ Other patients deemed difficult to study

Who the study is looking for

① Diagnosed with gastric adenocarcinoma by tissue biopsy and capable of middle segmental gastrectomy by meeting the following oncologic characteristics on preoperative examination
The tumor is located in the mid body or high body
The tumor is 4 cm or less in size as described in endoscopy
cT1N0 or cT1N1, any differentiation
-cT2N0 or T2N1, well-differentiated or moderately-differentiated adenocarcinoma
- Adult patients age 20 and older ③ ECOG performance is between 0 and 2
- ASA score class I - III
- Signed written informed consent, approved by the institutional review board, to participate in this study freely and voluntarily, after being fully informed of the purpose, content, and risks of the study prior to participation.

Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
National Cancer Center Korea Coordinator of this site? Confirm its status	Goyang	South Korea	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.